Routine filing: Registrar confirms Q2 demat activity processed

Compliance View source PDF Explain this filing

SYMBIOTEC · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-1.1%Reaction day

₹1166.00

prior close

₹1168.90

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+1.3%-2.5% vs market

On the reaction day the stock moved 2.5 pts less than Nifty Microcap 250, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.2

10m

-0.5

15m

+0.7

30m

+0.4

Sessions after the filingfrom the prior close

StockMarketvs market

Reaction day

-1.1+1.3-2.5

Next day

-3.3+1.1-4.3

-6.0-1.7-4.3

-6.8-1.5-5.4

-5.8-0.6-5.2

+0.7-0.4+1.1

+6.8-1.4+8.2

15d

———

UpDownMarket · Nifty Microcap 250Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Symbiotec Pharmalab has submitted to BSE and NSE a certificate from its Registrar MUFG Intime India under SEBI Regulation 74(5) for the quarter ended September 30, 2026. The certificate confirms that all share certificates received for dematerialisation during the period were verified, confirmed or rejected, and the corresponding entries in the register of members were updated within the prescribed timelines. The company has also hosted the certificate on its investor website.

Likely market impact

Routine procedural compliance filing. No material impact on operations, financials or shareholders.